Whenever the topic of research firms and life sciences came up, a chill blew through the room.</p><p>The issue of Scripps came up multiple times, Rodriguez said.</p><p>The reaction around the table: At best it was dubious, at worst it was outright people unbelieving of the merits of this type of investment.</p><p>Rodriguez, though, is a believer.